Vaxinano Information

Vaxinano: a new-generation vaccine platform. Vaxinano is a biotechnology company based near Lille, specialising in the development of prophylactic and therapeutic vaccines to combat infectious diseases in animal and human health. We offer a vaccine platform from which innovative non-adjuvanted vaccines are developed. This platform not only makes it possible to develop new vaccines and improve existing vaccines (by replacing adjuvants), but also to reduce or even replace the use of antibiotics. The patented technology is based on biosourced nanoparticles (starch and lipids) manufactured according to the principles of green chemistry and Good Manufacturing Practice (GMP). They are used as a powerful antigen delivery system. Vaccine formulations from this platform can be administered via the nasal route, as the nanoparticles are able to penetrate mucus, or via injection. Vaxinano has achieved two world firsts with an immunotherapeutic treatment for leishmaniasis and an inactivated vaccine against toxoplasmosis. Vaxinano is the first company to develop inactivated, non-adjuvanted nasal vaccines with proven efficacy against bacterial, parasitic and viral diseases.